Odronextamab recommended for eu approval by the chmp to treat relapsed/refractory follicular lymphoma and diffuse large b-cell lymphoma

Recommendation based on data from the phase 1 and pivotal phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large b-cell lymphoma recommendation based on data from the phase 1 and pivotal phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large b-cell lymphoma
REGN Ratings Summary
REGN Quant Ranking